bartsch rupert (10 Ergebnisse)

Zustand: Gebraucht - Sehr gut. SPRINGER VERLAG - 2011 - H4.

Zustand: Sehr gut. Zustand: Sehr gut | Sprache: Englisch | Produktart: Bücher | Growth factor receptors have long been known to drive malignant transformation and cancer progression. The epidermal growth factor receptor (EGFR, ErbB, HER) system is likely the best described membrane receptor tyrosine kinase family in malignant tumors. With implementation of the growth-inhibitory anti-HER-2 antibody trastuzumab (Herceptin) for the treatment of HER-2-positive advanced metastatic breast cancer, a new era has dawned in the therapy of this malignant disease. Unfortunately, trastuzumab-sensitive cancers invariably develop resistance to the antibody after some time. Recent clinical studies have revealed that these refractory tumors are still responsive to inhibition of the HER receptor family using dual HER-1/-2 inhibitors such as lapatinib (Tykerb/Tyverb). Moreover, a multiplicity of novel, improved irreversibly acting small molecular HER tyrosine kinase inhibitors are in the pipeline of many drug developing companies and are being evaluated in the clinical setting.

Zustand: New. In.

Zustand: New. In.

Taschenbuch. Zustand: Neu. Drugs for HER-2-positive Breast Cancer | Maria Sibilia (u. a.) | Taschenbuch | Milestones in Drug Therapy | x | Englisch | 2013 | Springer | EAN 9783034803182 | Verantwortliche Person für die EU: Springer Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg, juergen[dot]hartmann[at]springer[dot]com | Anbieter: preigu.

Buch. Zustand: Neu. Druck auf Anfrage Neuware - Printed after ordering - Growth factor receptors have long been known to drive malignant transformation and cancer progression. The epidermal growth factor receptor (EGFR, ErbB, HER) system is likely the best described membrane receptor tyrosine kinase family in malignant tumors. With implementation of the growth-inhibitory anti-HER-2 antibody trastuzumab (Herceptin) for the treatment of HER-2-positive advanced metastatic breast cancer, a new era has dawned in the therapy of this malignant disease. Unfortunately, trastuzumab-sensitive cancers invariably develop resistance to the antibody after some time. Recent clinical studies have revealed that these refractory tumors are still responsive to inhibition of the HER receptor family using dual HER-1/-2 inhibitors such as lapatinib (Tykerb/Tyverb). Moreover, a multiplicity of novel, improved irreversibly acting small molecular HER tyrosine kinase inhibitors are in the pipeline of many drug developing companies and are being evaluated in the clinical setting.

Taschenbuch. Zustand: Neu. Druck auf Anfrage Neuware - Printed after ordering - Growth factor receptors have long been known to drive malignant transformation and cancer progression. The epidermal growth factor receptor (EGFR, ErbB, HER) system is likely the best described membrane receptor tyrosine kinase family in malignant tumors. With implementation of the growth-inhibitory anti-HER-2 antibody trastuzumab (Herceptin) for the treatment of HER-2-positive advanced metastatic breast cancer, a new era has dawned in the therapy of this malignant disease. Unfortunately, trastuzumab-sensitive cancers invariably develop resistance to the antibody after some time. Recent clinical studies have revealed that these refractory tumors are still responsive to inhibition of the HER receptor family using dual HER-1/-2 inhibitors such as lapatinib (Tykerb/Tyverb). Moreover, a multiplicity of novel, improved irreversibly acting small molecular HER tyrosine kinase inhibitors are in the pipeline of many drug developing companies and are being evaluated in the clinical setting.

Paperback. Zustand: Brand New. 2011 edition. 119 pages. 9.25x6.10x0.28 inches. In Stock.

Hardcover. Zustand: Brand New. 1st edition. 110 pages. 9.25x6.50x0.50 inches. In Stock.

Zustand: New. Growth factor receptors have long been known to drive malignant transformation and cancer progression. With implementation of the growth-inhibitory anti-HER-2 antibody trastuzumab for the treatment of HER-2-positive advanced metastatic breast cancer, a new era has dawned in the therapy of this malignant disease. Thsi book deals with this topic. Editor(s): Zielinski, Christoph C.; Sibilia, Maria; Bergen, Elisabeth; Grunt, Thomas W.; Bartsch, Rupert. Series: Milestones in Drug Therapy. Num Pages: 120 pages, biography. BIC Classification: MJCL; MJCM; MMG. Category: (P) Professional & Vocational. Dimension: 244 x 164 x 14. Weight in Grams: 384. . 2011. Hardback. . . . . Books ship from the US and Ireland.